AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 296: R786-R793, 2009. First published December 10, 2008; doi:10.1152/ajpregu.90694.2008
0363-6119/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/3/R786    most recent
90694.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kramer, J.
Right arrow Articles by Wachtman, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kramer, J.
Right arrow Articles by Wachtman, L. M.

COMPARATIVE AND EVOLUTIONARY PHYSIOLOGY

Differential expression of GLUT2 in pancreatic islets and kidneys of New and Old World nonhuman primates

Joshua Kramer, Elisabeth Ludlage Moeller, Audra Hachey, Keith G. Mansfield, and Lynn M. Wachtman

Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts

Submitted 15 August 2008 ; accepted in final form 2 December 2008

Diabetes is a growing public health concern, and animal models of this disease are necessary for a full understanding of disease pathogenesis, progression, clinical sequelae, and treatment options. In particular, nonhuman primate models of diabetes are important because of their close genetic relationship to humans. Although numerous Old World primate models have been described, few studies have examined the possibility of using New World monkeys as an animal model for this disease. Streptozotocin (STZ) is a common diabetogenic drug that selectively destroys beta cells after uptake via the GLUT2 glucose transporter. Induction of diabetes using STZ was attempted in common marmosets (Callithrix jacchus). These animals showed increases in blood glucose consistent with diabetes only at STZ doses markedly greater than those used in other primate species. Additionally, all animals showed pathological evidence of acute renal and liver toxicity secondary to the treatment. In a subsequent comparative study of various nonhuman primates, GLUT2 immunostaining in pancreatic islets was used as a marker for sensitivity to STZ. Immunostaining of islets from a variety of nonhuman primate species indicated a reduced expression of pancreatic GLUT2 in New compared with Old World monkeys; this finding explains their resistance to diabetic induction with STZ. Furthermore, there were age-dependent differences in GLUT2 expression, with aged and infant macaques showing reduced expression. We conclude that New World monkeys are an inappropriate model for diabetes induction with STZ and that, with all primate species, it is important to consider the animals’ age before diabetic induction with STZ is attempted.

diabetes mellitus; streptozotocin; common marmoset



Address for reprint requests and other correspondence: L. M. Wachtman, Harvard Medical School, New England Primate Research Center, 1 Pine Hill Dr., Southborough, MA 01772-9102 (e-mail: lynn_wachtman{at}hms.harvard.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.